上肢静脉血栓形成后血栓后综合征、复发性血栓栓塞及出血发生率的系统综述与荟萃分析
该系统综述与荟萃分析纳入55项研究共15694例上肢静脉血栓形成患者,评估复发性静脉血栓栓塞、出血和血栓后综合征的汇总比例。复发性静脉血栓栓塞为4.8%,大出血为3.0%,血栓后综合征为23.8%;直接口服抗凝药治疗者血栓后综合征比例低于其他抗凝药。
要点
- 上肢静脉血栓形成后血栓后综合征汇总比例为23.8%(95%CI 17.0%-32.3%)。
- 复发性静脉血栓栓塞汇总比例为4.8%(95%CI 3.8%-6.2%),大出血为3.0%(95%CI 2.2%-4.0%)。
- 直接口服抗凝药治疗者血栓后综合征比例为11.8%,低于低分子肝素(27.9%)和维生素K拮抗剂(24.5%),P=.02。
核心结论
- 上肢静脉血栓形成与显著的血栓后综合征和复发性静脉血栓栓塞发生率相关。
- 直接口服抗凝药治疗可能与较低的血栓后综合征发生率相关。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library数据库2000年1月至2023年4月发表的英文文献,遵循PRISMA指南。
- 共纳入55项研究、15694例上肢静脉血栓形成患者,排除Paget-Schroetter综合征或用力性血栓形成患者。
- 对复发性静脉血栓栓塞、出血和血栓后综合征进行荟萃分析计算汇总估计值和95%置信区间,并进行癌症相关和导管相关静脉血栓形成的亚组分析。
主要发现
- 复发性静脉血栓栓塞汇总比例为4.8%(95%CI 3.8%-6.2%),大出血为3.0%(95%CI 2.2%-4.0%),血栓后综合征为23.8%(95%CI 17.0%-32.3%)。
- 复发性静脉血栓栓塞汇总比例:直接口服抗凝药治疗者2.7%(95%CI 1.6%-4.6%),低分子肝素治疗者1.7%(95%CI 0.8%-3.7%),维生素K拮抗剂治疗者4.4%(95%CI 1.5%-11.8%),P=.36。
- 复发性静脉血栓栓塞汇总比例:癌症患者6.3%(95%CI 4.3%-9.1%),非癌症患者3.1%(95%CI 2.1%-4.6%),P=.01。
- 大出血汇总比例:直接口服抗凝药治疗者2.1%(95%CI 0.9%-5.1%),低分子肝素治疗者3.2%(95%CI 1.4%-7.2%),维生素K拮抗剂治疗者3.4%(95%CI 1.4%-8.4%),P=.72。
- 血栓后综合征汇总比例:直接口服抗凝药治疗者11.8%(95%CI 6.5%-20.6%),低分子肝素治疗者27.9%(95%CI 20.9%-36.2%),维生素K拮抗剂治疗者24.5%(95%CI 17.6%-33.1%),P=.02。
临床怎么用
- 原文结论指出上肢静脉血栓形成与显著的血栓后综合征和复发性静脉血栓栓塞发生率相关。
- 作者认为直接口服抗凝药治疗可能与较低的血栓后综合征发生率相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on complications after upper extremity vein thrombosis (UEVT) are limited and heterogeneous. METHODS: The aim of the present study was to evaluate the pooled proportions of venous thromboembolism (VTE) recurrence, bleeding, and post-thrombotic syndrome (PTS) in patients with UEVT. A systematic literature review was conducted of PubMed, Embase, and the Cochrane Library databases from January 2000 to April 2023 in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. All studies included patients with UEVT and were published in English. Meta-analyses of VTE recurrence, bleeding, and of PTS after UEVT were performed to compute pooled estimates and associated 95% confidence intervals (CIs). Subgroup analyses of cancer-associated UEVT and catheter-associated venous thrombosis were conducted. Patients with Paget-Schroetter syndrome or effort thrombosis were excluded. RESULTS: A total of 55 studies with 15,694 patients were included. The pooled proportions for VTE recurrence, major bleeding, and PTS were 4.8% (95% CI, 3.8%-6.2%), 3.0% (95% CI, 2.2%-4.0%), and 23.8% (95% CI, 17.0%-32.3%), respectively. The pooled proportion of VTE recurrence was 2.7% (95% CI, 1.6%-4.6%) for patients treated with direct oral anticoagulants (DOACs), 1.7% (95% CI, 0.8%-3.7%) for patients treated with low-molecular-weight heparin (LMWH), and 4.4% (95% CI, 1.5%-11.8%) for vitamin K antagonists (VKAs; P = .36). The pooled proportion was 6.3% (95% CI, 4.3%-9.1%) for cancer patients compared with 3.1% (95% CI, 2.1%-4.6%) for patients without cancer (P = .01). The pooled proportion of major bleeding for patients treated with DOACs, LMWH, and VKAs, was 2.1% (95% CI, 0.9%-5.1%), 3.2% (95% CI, 1.4%-7.2%), and 3.4% (95% CI, 1.4%-8.4%), respectively (P = .72). The pooled proportion of PTS for patients treated with DOACs, LMWH, and VKAs was 11.8% (95% CI, 6.5%-20.6%), 27.9% (95% CI, 20.9%-36.2%), and 24.5% (95% CI, 17.6%-33.1%), respectively (P = .02). CONCLUSIONS: The results from this study suggest that UEVT is associated with significant rates of PTS and VTE recurrence. Treatment with DOACs might be associated with lower PTS rates than treatment with other anticoagulants.
引用
- Espitia O, Raimbeau A, Planquette B, et al. A systematic review and meta-analysis of the incidence of post-thrombotic syndrome, recurrent thromboembolism, and bleeding after upper extremity vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37717788. doi:10.1016/j.jvsv.2023.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。